ALZAMEND NEURO, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
ALZAMEND NEURO, INC. (ALZN) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.20% for the 12-month period ending 2025-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-07-22
- ALZAMEND NEURO, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -0.20%.
- ALZAMEND NEURO, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.00%, a 100.00% decline from fiscal 2023.
- ALZAMEND NEURO, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 2.00%.
- ALZAMEND NEURO, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-04-30 | -0.20% 10-K · filed 2026-07-22 | |
| 2024-04-30 | 0.00% 10-K · filed 2026-07-22 | |
| 2023-04-30 | 2.00% 10-K · filed 2024-07-30 | |
| 2022-04-30 | 0.00% 10-K · filed 2023-07-27 | |
| 2021-04-30 | -2.20% 10-K · filed 2022-07-19 | -5.10% 10-K · filed 2021-07-29 |
| 2020-04-30 | -0.10% 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |